PYODERMA GANGRENOSUM
Clinical trials for PYODERMA GANGRENOSUM explained in plain language.
Never miss a new study
Get alerted when new PYODERMA GANGRENOSUM trials appear
Sign up with your email to follow new studies for PYODERMA GANGRENOSUM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug for rare skin ulcers shows early potential
Disease control TerminatedThis study tested a drug called spesolimab in 5 adults with moderate to severe pyoderma gangrenosum, a rare autoimmune disease that causes painful skin ulcers. The goal was to see if the drug could help heal the ulcers and to understand how the body's immune system responds. The …
Matched conditions: PYODERMA GANGRENOSUM
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Promising drug trial for painful skin ulcers halted early
Disease control TerminatedThis study tested a drug called vilobelimab for people with pyoderma gangrenosum, a rare condition causing painful skin ulcers. The trial aimed to see if the drug could completely close the ulcers compared to a placebo. It included 54 adults and was stopped early, so the results …
Matched conditions: PYODERMA GANGRENOSUM
Phase: PHASE3 • Sponsor: InflaRx GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New wound therapy for rare skin disease shows early promise
Disease control TerminatedThis study tested a treatment for pyoderma gangrenosum, a rare skin condition that causes painful, hard-to-heal ulcers. Researchers used a special wound covering made from donated placenta tissue (EpiFix) followed by skin grafts. The study was stopped early after only 5 people en…
Matched conditions: PYODERMA GANGRENOSUM
Phase: PHASE4 • Sponsor: Louisiana State University Health Sciences Center in New Orleans • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC